Vancomycin‐Resistant Enterococcal Urinary Tract Infections
Authors:
- 1 November 2010
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 30 (11) , 1136-1149
Abstract
Enterococci are a common cause of urinary tract infections (UTIs) among hospitalized patients. The rising prevalence of vancomycin‐resistant enterococci (VRE) is of particular concern within many institutions because of its association with increased mortality and health care costs, as well as limited treatment options. Clinicians need to differentiate between VRE‐associated urinary colonization, asymptomatic bacteriuria, and UTIs in order to determine the need for treatment, optimal therapeutic options, and length of therapy. Unnecessary use of antibiotics in patients simply colonized and not infected with VRE in the urine has become a large problem in both hospitals and long‐term care facilities. A PubMed‐MEDLINE search was conducted to identify all English‐language literature published between January 1975 and March 2010 in order to summarize diagnostic criteria and treatment options for VRE UTIs. Several antimicrobials are discussed, with the specific focus on those with the potential to treat VRE UTIs and susceptibility patterns of VRE from urinary sources: ampicillin, amoxicillin, daptomycin, doxycycline, fosfomycin, imipenem‐cilastatin, linezolid, nitrofurantoin, penicillin, piperacillin, quinupristin‐dalfopristin, tetracycline, and tigecycline. Recommendations for empiric treatment of enterococcal UTIs and definitive treatment of VRE UTIs, including an evidence‐based treatment algorithm, are proposed. Ampicillin generally is considered the drug of choice for ampicillin‐susceptible enterococcal UTIs, including VRE. Nitrofurantoin, fosfomycin, and doxycycline have intrinsic activity against enterococci, including VRE, and are possible oral options for VRE cystitis. Linezolid and daptomycin should be reserved for confirmed or suspected upper and/or bacteremic VRE UTIs among ampicillin‐resistant strains. Use of other antimicrobials, such as quinupristin‐dalfopristin and tigecycline, should be evaluated on a case‐by‐case basis due to concerns of toxicity, resistance, and insufficient supportive data. Additional clinical data are needed to determine the optimal management and duration of therapy for VRE UTIs.Keywords
This publication has 67 references indexed in Scilit:
- Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)Diagnostic Microbiology and Infectious Disease, 2009
- Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin TherapyAnnals of Pharmacotherapy, 2009
- Daptomycin Therapy for Vancomycin‐Resistant Enterococcal Bacteremia: A Retrospective Case Series of 30 PatientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infectionsInternational Journal of Antimicrobial Agents, 2009
- The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004Diagnostic Microbiology and Infectious Disease, 2008
- Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Increasing Incidence of Linezolid-Intermediate or -Resistant, Vancomycin-Resistant Enterococcus faecium Strains Parallels Increasing Linezolid ConsumptionAntimicrobial Agents and Chemotherapy, 2008
- Treatment of Recurrent Urosepsis with Tigecycline: a Pharmacological PerspectiveJournal of Clinical Microbiology, 2008
- Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patientsJournal of Infection, 2007
- Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006